{"filings":[{"id":563118,"accession_number":"0001140361-26-022311","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2026-05-21T10:02:22+00:00","items":["5.07"],"status":"ready","headline":"Rocket Pharmaceuticals stockholders elect directors, ratify auditor, approve say-on-pay and stock option exchange","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven director nominees elected; David P. Southwell received 43.2M for, 20.1M withheld (lowest support).","Ratification of EisnerAmper as independent auditor: 79.2M for, 1.0M against, 0.6M abstain.","Non-binding advisory vote on executive compensation approved: 61.4M for, 1.7M against, 0.2M abstain.","Stock option exchange program approved with 45.6M for, 17.6M against (significant opposition)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91901,"accession_number":"0001140361-26-019573","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rocket Pharma Q1 net loss $47.6M; KRESLADI gets FDA accelerated approval; PRV sold for $180M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $47.6M ($0.42/sh) narrowed from $61.3M ($0.56/sh) YoY.","Cash $144.4M + $180M PRV proceeds extend runway into Q2 2028.","FDA granted accelerated approval for KRESLADI in severe LAD-I in March 2026.","Monetized Rare Pediatric Disease PRV for $180M on April 28, 2026.","Pivotal Phase 2 trial of RP-A501 for Danon disease dosing reinitiated; RP-A701 first dosing expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91900,"accession_number":"0001140361-26-017275","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Rocket Pharmaceuticals sells Rare Pediatric Disease PRV for $180M, extending cash runway to Q2 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters definitive agreement to sell PRV for $180M in cash; closing subject to HSR antitrust waiting period.","PRV was awarded following FDA accelerated approval of KRESLADI (marnetegragene autotemcel) for LAD-I.","Non-dilutive capital to support cardiovascular pipeline: Danon disease, PKP2-ACM, BAG3-DCM programs.","Cash runway extended into second quarter of 2028, per CEO Gaurav Shah.","PRV program reauthorized in February 2026, reinforcing incentive for rare pediatric disease therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102307,"accession_number":"0001140361-26-011573","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA approves Rocket's gene therapy KRESLADI for severe LAD-I; Rare Pediatric PRV granted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["KRESLADI (marnetegragene autotemcel) approved for pediatric severe LAD-I with no HLA-matched sibling donor.","First FDA-approved gene therapy for severe LAD-I; accelerated approval based on CD18/CD11a expression.","FDA granted Rocket a Rare Pediatric Disease Priority Review Voucher; company plans to evaluate monetization.","Company to host investor conference call March 27 at 8:30 AM ET.","Phase 1/2 study principal investigator Donald Kohn, M.D., highlights years of research culminating in approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102306,"accession_number":"0001140361-26-008853","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Rocket Pharma enters $100M ATM equity facility with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Cantor Fitzgerald to sell up to $100M of common stock via at-the-market offerings.","Prior ATM agreement with Cowen/ TD Securities terminated upon signing new agreement.","Sales occur on Nasdaq; Cantor receives up to 3% commission on gross proceeds.","Shelf registration on Form S-3 filed March 2, 2026, declared effective March 10, 2026.","Company may suspend or terminate offerings at any time; no obligation to sell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102305,"accession_number":"0001140361-26-006981","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rocket Pharma FY2025 net loss $223.1M; cash $188.9M; KRESLADI PDUFA March 28, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $223.1M ($2.01/shr) vs $258.7M ($2.73/shr) in FY2024; R&D spend down 17% to $142.0M.","Cash, cash equivalents & investments $188.9M; runway into Q2 2027; restructuring charges $3.2M.","Pivotal Phase 2 trial of RP-A501 (Danon disease) to resume 1H 2026 after FDA lifted clinical hold.","KRESLADI BLA resubmission accepted; PDUFA target action date March 28, 2026; eligible for PRV.","First patient dosing in Phase 1 RP-A701 (BAG3-DCM) expected mid-2026; Phase 1 trial startup ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118594,"accession_number":"0001140361-25-040774","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rocket Pharma Q3 net loss $50.3M; KRESLADI PDUFA March 2026; Danon trial to resume 1H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $50.3M ($0.45/share), down from $66.7M ($0.71) YoY; R&D expenses $34.1M vs $42.3M.","Cash, equivalents, investments $222.8M; runway expected into Q2 2027.","FDA accepted KRESLADI (marne-cel) BLA resubmission for severe LAD-I; PDUFA target March 28, 2026.","Phase 2 trial of RP-A501 for Danon disease to resume dosing in 1H 2026 after FDA lifted clinical hold.","Appointed Dr. Syed Rizvi as CMO, Christopher Stevens as COO, Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118593,"accession_number":"0001140361-25-038030","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rocket Pharma: FDA accepts BLA resubmission for KRESLADI gene therapy; PDUFA March 28, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA resubmission for KRESLADI (marne-cel) for severe LAD-I; PDUFA target date March 28, 2026.","Phase 1/2 study showed 100% overall survival at 12 months; all endpoints met; well tolerated with no treatment-related SAEs.","Company eligible for Rare Pediatric Disease Priority Review Voucher if KRESLADI is approved.","Severe LAD-I is near-uniformly fatal in childhood; only current treatment is bone marrow transplant with substantial morbidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118592,"accession_number":"0001140361-25-037237","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Pedro Granadillo resigns from Rocket Pharmaceuticals board effective Sept 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pedro Granadillo resigned from Board on Sept 29, 2025, effective Sept 30, 2025.","Resignation not due to any disagreement on operations, policies, or practices.","No replacement announced; remaining directors continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118591,"accession_number":"0001140361-25-037163","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rocket Pharma withdraws BLA for RP-L102 (Fanconi anemia gene therapy) as part of corporate prioritization","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntarily withdrew BLA for RP-L102 (mozafancogene autotemcel) from FDA on October 3, 2025.","Withdrawal follows prior MAA withdrawal to European Medicines Agency in July 2025 and cessation of new internal investment in RP-L102 in July 2025.","Decision based on business and strategic considerations; no safety or efficacy concerns noted.","Company will explore external partnership opportunities to potentially advance RP-L102 in the future.","Rocket is focusing resources on programs with clearest regulatory and commercial pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135069,"accession_number":"0001140361-25-036556","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rocket Pharmaceuticals appoints Dr. Peter Fong to Board; Dr. Gotham Makker resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gotham Makker resigned from the Board effective Sept 24, 2025; no disagreement on operations, policies, or practices.","Dr. Peter Fong, President of RTW Investments LP, appointed to Board effective Sept 24, 2025.","Fong receives 30,000 RSUs vesting in equal monthly installments over three years.","Fong also receives 23,333 RSUs vesting fully on the first anniversary of grant date.","No family relationships or related person transactions between Fong and the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135068,"accession_number":"0001140361-25-035251","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Rocket Pharma finalizes Dr. Patel separation; consulting through Dec 2026 with $582K retainer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kinnari Patel receives $482,040 lump-sum severance (10 months salary) and $30,045 healthcare allowance.","She stays on paid garden leave through Dec 31, 2025; then consulting until Dec 31, 2026 for $582,156 retainer.","Patel retains restricted stock units and options during the consulting period under existing plans.","Accrued PTO payout of $102,480; 2025 bonus eligibility subject to company performance.","Payments conditioned on release of claims, non-disparagement, and restrictive covenant compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135067,"accession_number":"0001140361-25-032502","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rocket Pharma CFO resigns; General Counsel named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aaron Ondrey resigned as CFO effective September 5, 2025 to pursue other opportunities.","Martin Wilson, General Counsel and Chief Corporate Officer, appointed interim Principal Financial Officer effective September 8, 2025.","Wilson joined Rocket in November 2021; has nearly 20 years of life sciences legal and executive experience.","No family relationships or transactions with the company beyond compensation for current roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135066,"accession_number":"0001140361-25-032012","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rocket Pharmaceuticals: FDA lifts clinical hold on Phase 2 trial of RP-A501 for Danon disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted clinical hold in under 3 months; trial resumes with recalibrated dose 3.8x10^13 GC/kg for 3 patients with 4-week intervals.","Revised immunomodulatory regimen: discontinue prophylactic C3 inhibitor, maintain sirolimus/rituximab/steroids, lower eculizumab threshold.","Phase 2 trial is 12-patient single-arm; co-primary endpoint: LAMP2 expression and left ventricular mass reduction; key secondary: troponin change.","Six patients previously treated at 6.7x10^13 GC/kg; three additional at lower dose to be treated sequentially.","Natural history study running concurrently; all patients require 3-month pre-treatment run-in for biomarker assessment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135065,"accession_number":"0001140361-25-029582","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Rocket Pharmaceuticals: President Patel to depart, 30% workforce cut, Q2 net loss $68.9M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kinnari Patel to leave as President and Head of R&D effective Dec 31, 2025; steps down Aug 8.","Workforce reduction of ~30% and cash burn cut ~25% as part of strategic restructuring.","Q2 net loss $68.9M ($0.62/share); cash $271.5M; expects runway into Q2 2027.","Clinical hold on RP-A501 Danon disease trial ongoing after patient death; engaging with FDA.","Chris Stevens appointed COO in July; former Spark Therapeutics executive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135064,"accession_number":"0001140361-25-027032","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rocket Pharma restructures, cuts headcount 30%, delays FA/PKD programs; cash runway to Q2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Headcount reduction of ~30% and 12-month cash burn reduction of ~25% as part of corporate reorganization.","Pipeline focus on AAV cardiovascular programs (Danon, PKP2-ACM, BAG3-DCM) and KRESLADI for severe LAD-I.","Cash runway extended into Q2 2027; excludes any potential proceeds from Priority Review Voucher for KRESLADI.","Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301) programs delayed; FDA OK for RP-L102 no longer expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135063,"accession_number":"0001140361-25-026946","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Rocket Pharmaceuticals cuts workforce 30%, extends cash runway into Q2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in workforce of ~30%; expected to cut 12-month operating expenses by ~25%.","Estimated $3.5M in restructuring charges in H2 2025; severance for ~80 employees.","Board approved Plan on June 18, 2025; RIF began July 23, to be completed by August 8, 2025.","Restructuring aims to maximize near-term value and extend operational runway into Q2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135062,"accession_number":"0001140361-25-026132","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants RMAT designation to Rocket Pharma's RP-A601 gene therapy for PKP2-ACM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted RMAT designation for RP-A601 (AAV-based gene therapy) for PKP2-arrhythmogenic cardiomyopathy.","RMAT provides expedited FDA review, early interactions, and potential accelerated approval.","Phase 1 data: two patients with low baseline PKP2 showed 110% and 398% increases in protein expression.","Improvements in right ventricular function, ventricular arrhythmias, and KCCQ-12 scores (34-41 pts).","Fifth RMAT designation for Rocket; favorable safety with no dose-limiting toxicities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135061,"accession_number":"0001140361-25-025673","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rocket Pharmaceuticals appoints Christopher Stevens as COO; Patel shifts to President, Head of R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Stevens, age 45, appointed COO effective July 7, 2025; previously EVP at Spark Therapeutics.","Kinnari Patel transitions from COO, President, Head of R&D to President, Head of R&D.","Stevens receives $525,000 base salary, 45% target bonus, $250,000 sign-on, and ~$2.5M equity grant.","Equity vests over 3 years; additional $500K equity grant after one year.","Severance provisions: 9 months base plus COBRA; 12 months on change-in-control termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152040,"accession_number":"0001140361-25-022996","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rocket Pharma annual meeting: all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["10 director nominees elected; David P. Southwell received 55.4M for vs 23.8M withheld, still elected on plurality standard.","Ratification of EisnerAmper as auditor approved with 90.7M votes for, 141.8K against, 528.3K abstentions.","Non-binding advisory vote on executive compensation passed with 77.2M for, 1.4M against, 515K abstentions.","Turnout of 91.4M shares (85.56% of eligible) voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152039,"accession_number":"0001140361-25-020409","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rocket Pharma announces FDA clinical hold on Phase 2 Danon gene therapy trial after patient death","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Patient in Phase 2 trial of RP-A501 experienced SAE (capillary leak syndrome) and later died due to acute systemic infection.","FDA placed clinical hold on May 23, 2025; company had voluntarily paused dosing earlier.","Root cause analysis focusing on novel immune suppression agent added to pre-treatment regimen for complement activation.","Company unable to provide guidance on trial completion timing.","Cash $318.2M as of March 31, 2025; expects to fund operations into 2027 with reduced spend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152038,"accession_number":"0001140361-25-019326","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rocket Pharma reports positive Phase 1 data for RP-A601 in PKP2-ACM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RP-A601 well-tolerated; no dose-limiting toxicities in 3 patients with up to 12 months follow-up.","PKP2 protein expression increased ~110% and ~398% from baseline in 2 patients with low expression.","Improved RV function, KCCQ-12 scores (34-41 points), and NYHA class (II to I) in patients.","PVCs reduced 9-63%; NSVT episodes eliminated in one patient. No further dose escalation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152037,"accession_number":"0001140361-25-017958","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rocket Pharma Q1 net loss $61.3M; cash $318.2M; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $61.3M ($0.56/share) vs $62.1M in Q1 2024; R&D expenses down to $35.9M.","Cash, equivalents, investments $318.2M; operational runway into Q4 2026.","Phase 2 RP-A501 for Danon disease ongoing; program update mid-2025, data mid-2026.","Initial Phase 1 data for RP-A601 (PKP2-ACM) expected May 2025; IND for BAG3-DCM mid-2025.","Rolling BLA for RP-L102 (Fanconi Anemia); final module late 2025/early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152036,"accession_number":"0001140361-25-016338","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director R. Keith Woods not standing for re-election to Rocket board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["R. Keith Woods informed board he accepted COO role at another biopharma company; will not stand for re-election at 2025 annual meeting.","His term as director and membership on audit and commercial committees ends at the 2025 annual meeting.","Departure is not due to any disagreement with Rocket's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152035,"accession_number":"0001140361-25-012621","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rocket Pharma appoints Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $525,000 with a target bonus of 45% of salary.","Equity grant of ~$2,500,000 (50% options, 50% RSUs) vesting over three years.","One-third of RSUs/options vest at first anniversary; remainder over two years quarterly.","Sign-on bonus of $100,000 payable 30 days after start date, contingent on employment.","Severance of 9 months salary plus COBRA; 12 months salary/bonus/COBRA on qualifying change-in-control termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170869,"accession_number":"0001140361-25-006302","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rocket Pharma FY2024 net loss $258.7M ($2.73/sh); cash $372.3M; RP-A501 Phase 2 ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $258.7M ($2.73/sh) for FY2024 vs $245.6M ($2.92/sh) in FY2023.","Cash, equivalents and investments $372.3M at Dec 31, 2024; runway into Q3 2026.","Raised $182.5M net via Dec 2024 offering of 15.2M shares at $12.50/sh.","RP-A501 Phase 2 pivotal dosing ongoing; NEJM publication shows efficacy up to 5 years.","RP-A601 low dose cohort fully enrolled; initial data expected H1 2025. BAG3-DCM IND on track H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170868,"accession_number":"0001140361-25-002103","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rocket Pharmaceuticals appoints Piratip Pratumsuwan to Board; Yalamanchi resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Naveen Yalamanchi resigned from Board effective Jan 25, 2025; no disagreement.","Piratip Pratumsuwan appointed to Board effective Jan 27, 2025.","Pratumsuwan is Managing Director, Research Analyst at RTW Investments, specializing in gene therapy.","Received option grants: $360k (3-year monthly vest) and $155k (1-year cliff vest).","Age 33; M.A. in Biotechnology from Columbia, B.S. in Biochemistry from McGill."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187831,"accession_number":"0001140361-24-049137","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Rocket Pharmaceuticals raises ~$182.8M in public offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 15.18M shares at $12.50/sh, including full exercise of underwriters' option; net proceeds ~$178.1M.","Private placement of 400,000 pre-funded warrants at $12.49 to RTW Innovation Master Fund, net proceeds ~$4.7M.","Proceeds to fund pipeline development, commercialization preparedness, and general corporate purposes.","45-day lock-up on sales of common stock by officers, directors, and certain shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187830,"accession_number":"0001140361-24-048475","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rocket Pharma GM Commercial Affairs Mark White resigns effective Jan 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark White resigns as General Manager, Commercial Affairs, effective January 1, 2025.","No successor has been named.","The company did not disclose a reason for the resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187829,"accession_number":"0001140361-24-047166","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rocket Pharma reports positive long-term Phase 1 Danon Disease data; PKD program enrollment delayed to 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All evaluable Danon disease patients showed cardiac LAMP2 protein expression at 12 months, sustained up to 60 months, and ≥10% LV mass index reduction sustained up to 54 months.","Median reduction in LV mass index 24%; cardiac biomarkers cTnI down 84%, NTproBNP down 57%; NYHA class improved II to I; KCCQ score improved 27 points.","RP-A501 generally well tolerated with manageable AEs; one patient with baseline LVEF<40% required heart transplant 5 months post-treatment.","Phase 2 pivotal trial for Pyruvate Kinase Deficiency (RP-L301) design agreed with FDA; enrollment not started, anticipates resuming in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187828,"accession_number":"0001140361-24-045670","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rocket Pharma Q3 2024 net loss $198.4M; cash $235.7M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $198.4M ($2.11/share) for nine months ended Sept 30, 2024, vs $185.9M ($2.30/share) prior year.","Cash $235.7M as of Sept 30; expects runway into 2026.","R&D expenses $133.9M (down from $144.6M); G&A $76.6M (up from $51.8M) due to commercial prep.","Completed enrollment in Phase 2 pivotal study of RP-A501 for Danon disease; dosing ongoing.","Initiated rolling BLA for RP-L102 for Fanconi Anemia; FDA approval for KRESLADI anticipated 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204347,"accession_number":"0001140361-24-040837","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rocket Pharmaceuticals appoints Dr. Mikael Dolsten to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mikael Dolsten appointed to board effective September 9, 2024.","Dolsten is Chief Scientific Officer and President, Pfizer R&D since July 2023.","Granted options to purchase 27,545 shares (vesting over 3 years) and 22,988 shares (vesting in 1 year) at closing market price.","Entered standard indemnification agreement with the company.","No arrangements with other persons or family relationships with directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204346,"accession_number":"0001140361-24-035756","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rocket Pharma H1 2024 net loss $131.7M; KRESLADI review ongoing, cash into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $131.7M ($1.40/sh) for H1 2024 vs $124.0M ($1.55/sh) for H1 2023.","Cash, equivalents & investments $278.8M; runway expected into 2026.","FDA requested additional CMC info for KRESLADI (LAD-I); working to support approval.","Phase 2 pivotal enrollment ongoing for RP-A501 (Danon) and RP-L301 (PKD) initiated.","EC granted orphan medicinal product designation for RP-A601 (PKP2-ACM); Phase 1 enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221111,"accession_number":"0001140361-24-031749","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rocket Pharma receives FDA Complete Response Letter for KRESLADI BLA; limited CMC info requested","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Complete Response Letter for KRESLADI (marne-cel) BLA; requested limited additional CMC information.","Company met with FDA CBER senior leaders to align on scope of additional CMC info to support approval expeditiously.","Phase 1/2 data: 100% overall survival at 12 months in 9 patients; all endpoints met; no treatment-related serious AEs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221110,"accession_number":"0001140361-24-030718","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Rocket Pharma increases authorized shares to 180M after shareholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 120M to 180M (50% increase); amendment effective June 20, 2024.","All ten director nominees elected; highest vote totals over 71M 'for' votes.","Ratification of EisnerAmper as independent auditor for FY 2024 approved by ~99.9% of votes cast.","Non-binding advisory vote on named executive officer compensation passed with ~98.4% of votes cast.","Voter turnout approximately 87.95% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221109,"accession_number":"0001140361-24-024574","cik":1281895,"company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKT","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rocket Pharma Q1 net loss $62.1M; cash $330.3M; EMA accepted MAA for FA, PDUFA date June 30 for LAD-I","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $62.1M ($0.66/sh) vs $58.3M ($0.73/sh) in Q1 2023; G&A rose to $22.1M on commercial prep.","Cash and investments $330.3M as of March 31, 2024; expected operational runway into 2026.","EMA accepted MAA for RP-L102 (Fanconi Anemia); BLA submission to FDA expected H1 2024.","PDUFA date for KRESLADI (severe LAD-I) set for June 30, 2024; commercial preparations underway.","Appointed Aaron Ondrey as CFO and Meg Dodge as VP of Investor Relations & Corporate Communications."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326488714.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}